Ariad Advances Drug for Resistant Leukemia Patients with MolecularMD's Companion Test

"The MolecularMD companion diagnostic test is being developed to identify CML and Ph+ ALL patients who have the T315I mutation," Ariad said in a statement, adding that a companion diagnostic test "is not necessary to support the broader potential use of ponatinib," since many other mutations contribute to patients' resistance to BCR-ABL inhibitors.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.